EUCTR2004-000915-25-LT进行中（未招募）不适用
Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients - SPaRCLe
AstraZeneca R&D Sodertalje0 个研究点目标入组 2,100 人开始时间: 2005年2月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the Open-label Treatment Phase patients must fulfill all of the following criteria:
- •1. Provide written informed consent before initiation of any study-related procedures
- •2. A diagnosis of Bipolar I Disorder, Most Recent Episode Manic (296.4x), Bipolar I Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most Recent Episode Mixed (296.6x), with or without psychotic features, as defined by Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV)
- •3. Male or female aged more than or equal to 18 years
- •4. At least 1 manic, depressed or mixed episode in the 2 years prior to the index episode
- •5. One of the following:
- •a. A current manic, depressed or mixed episode by DSM-IV criteria
- •b. A past manic, depressed or mixed episode within 26 weeks as documented by medical records, that was treated with quetiapine. Since this episode, treatment with quetiapine must not have been interrupted for more than 2 weeks continuously
- •6. Female patients of childbearing potential must be using a reliable method of contraception. Reliable methods of contraception include hormonal contraceptives (e.g., oral contraceptive or long-term injectable or implantable hormonal contraceptive), double-barrier methods (e.g., condom and diaphragm, condom and foam, condom and sponge), intrauterine devices, and tubal ligation
- •7. Able to understand and comply with the requirements of the study
- •For inclusion in the Randomized Treatment Phase, patients must fulfill all of the following criteria during the Open-label Treatment Phase:
- •1. Has been prescribed a dose of quetiapine within the range 300-800 mg/day for the last 4 weeks
- •2. YMRS less than or equal to 12 and MADRS less than or equal to 12 at all assessments during the last 4 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria for entering the Open-label Treatment Phase
- •Any of the following is regarded as a criterion for exclusion from the study at enrollment:
- •1. Diagnosis of an anxiety disorder as defined by DSM-IV, which was treated with medication within the past year
- •2. Known intolerance or lack of response to quetiapine fumarate or to lithium, as judged by the investigator
- •3. Pregnancy or lactation. Female patients of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) test at enrollment
- •4. Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM IV criteria
- •5. Opiate, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrollment
- •6. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, and saquinavir
- •7. Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John’s Wort, and glucocorticoids
- •8. Thyroid stimulating hormone (TSH) concentration more than 10% above the upper limit of the normal range, regardless of treatment for hypothyroidism or hyperthyroidism
- •9. Unstable or inadequately treated medical illness (e.g., angina pectoris and hypertension) as judged by the investigator
- •10. A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:
- •- Unstable DM defined as enrollment Glycosylated hemoglobin (HbA1c) >8.5%
- •- Admitted to hospital for treatment of DM or DM related illness in past 12 weeks
- •- Not under care of physician responsible for patient’s DM care
- •- Physician responsible for patient’s DM care has not indicated that patient’s DM is controlled
- •- Physician responsible for patient’s DM care has not approved patient’s participation in the study
- •- Has not been on the same dose of oral hypoglycemic drug(s) and/or diet for the 4 weeks prior to randomization. For thiazolidinediones (glitazones) this period should not be less than 8 weeks
- •- Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks
- •Note: If a diabetic patient meets one of these criteria the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study
- •11. Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
- •12. Use of an experimental drug within 30 days of enrollment
- •13. Previously enrolled into this study, study D1447C00126 or study D1447C00127
- •14. Involvement in the planning and conduct of the study (applies to both AstraZeneca, Quintiles staff or staff at the investigational site)
- •Exclusion criteria for entering the Randomized Treatment Phase
- •Any of the following is regarded as a criterion for exclusion from the study:
- •1. Hospitalization due to a mood event (manic, depressed or mixed) during the Open-label Treatment Phase
- •2. Electroconvulsive therapy (ECT) during the Open-label Treatment Phase
- •3. Attempt to commit suicide or homicide during the Open-label Treatment Phase
- •4. Substance or alcohol dependence (except dependence in full remission, and exce
研究者
相似试验
进行中（未招募）
1 期
Clinical trial in several centers in which patients are administrating randomly in parallel with treatment or placebo (control). Neither the researchers nor the patients know which treatment the patiens are receiving. Present clinical trial evaluates safety and clinical efficacy of intradermal immunotherapy with polymerised Phleum pratense, in patients with allergic rhino-conjunctivitis with or without mild to moderate asthma, sensitized to Phleum pratense pollen.Allergic patients to the pollen of Phleum pratense with allergic rhino-conjunctivitis with or without mild to moderate asthma.MedDRA version: 16.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2014-000429-18-ESDIATER, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas, S.A.174
已完成
不适用
Multicentre, parallel group, randomised, double blind study to investigate the efficacy of Montelukast (MK) + Fluticasone (FP) placebo versus Fluticasone + MK-placebo versus MK-placebo + FP-placebo in preschool children with asthma or asthma-like symptoms during a 3 months study periodAsthmaRespiratoryISRCTN38475879Merck Sharp and Dohme BV (Netherlands)150
未知
3 期
ubiprostone phase 3 double-blind studychronic idiopathic constipationJPRN-jRCT2080220730Sucampo Pharma, Ltd.116
进行中（未招募）
1 期
A research study to find out if aprocitentan is efficacious and safe to treat difficult to control (resistant) high blood pressure (hypertension)Resistant HypertensionEUCTR2017-004393-33-NLIdorsia Pharmaceuticals Ltd600
进行中（未招募）
1 期
A research study to find out if aprocitentan is efficacious and safe to treat difficult to control (resistant) high blood pressure (hypertension)MedDRA version: 20.0Level: LLTClassification code 10020783Term: Hypertension not adequately controlledSystem Organ Class: 100000004866Resistant HypertensionEUCTR2017-004393-33-ESIdorsia Pharmaceuticals Ltd730